CD Protein Inhibitors 

  Products    Products    Diseases    News 


«12...103104105106107108109110111112113...39323933»
  • ||||||||||  alvocidib (DSP-2033) / Sumitomo Pharma
    Journal:  Therapeutic potential of flavopiridol in diabetic retinopathy: Targeting DDX58. (Pubmed Central) -  Jul 10, 2024   
    Notably, our research demonstrated that flavopiridol modulates the DDX58/NLRP3 signaling pathway, thereby exerting its therapeutic effects in suppressing inflammation and neovascularization in DR. This study unveils groundbreaking therapeutic agents and innovative targets for DR, and establishes a progressive theoretical framework for the application of ubiquitin-related therapies in DR.
  • ||||||||||  Mekinist (trametinib) / Novartis, BeiGene, Keytruda (pembrolizumab) / Merck (MSD), Tafinlar (dabrafenib) / Novartis, BeiGene
    Review, Journal, Tumor mutational burden, PD(L)-1 Biomarker, IO biomarker, Metastases:  Promising Therapeutic Targets for Recurrent/Metastatic Anaplastic Thyroid Cancer. (Pubmed Central) -  Jul 10, 2024   
    The off-label utilization of "precision medicine" combinations imposes a considerable financial strain, underscoring the necessity for further clinical trials to elucidate promising therapeutic avenues for this orphan disease. There is a pressing need for the development and support of clinical trials investigating genomically driven and immune-based therapies for anaplastic thyroid cancer.
  • ||||||||||  Keytruda (pembrolizumab) / Merck (MSD), Opdivo (nivolumab) / BMS
    Journal:  Immunotherapy for patients with thyroid cancer: a comprehensive appraisal. (Pubmed Central) -  Jul 10, 2024   
    Additionally, other approaches like dendritic cell vaccination and radioimmunotherapy have been explored mainly for MTC, showing potential but requiring further investigation. While immunotherapy holds promise, especially in combination with other treatments, further research, and high-quality clinical trials are necessary to establish its effectiveness in treating advanced thyroid cancers.
  • ||||||||||  Yescarta (axicabtagene ciloleucel) / Gilead
    Journal, CAR T-Cell Therapy:  Toxic epidermal necrolysis-like cutaneous toxicity following chimeric antigen receptor T-cell therapy in recurrent large B-cell lymphoma. (Pubmed Central) -  Jul 10, 2024   
    We present a case of a 69-year-old man with diffuse large B-cell lymphoma treated with axicabtagene-ciloleucel CAR-T therapy, who developed a rare and severe cutaneous toxicity resembling toxic epidermal necrolysis (TEN)...Notably, allopurinol-induced TEN was considered with the patient's recent exposure to allopurinol, although the onset and minimal mucosal involvement did not align with typical presentations of allopurinol-induced cases...This case expands the spectrum of CAR-T therapy-related cutaneous toxicities, highlighting the need for early recognition of histopathology and tailored management by dermatologists. Further understanding of these reactions is crucial for optimizing the safety profile of this groundbreaking immunotherapy.
  • ||||||||||  dordaviprone (ONC201) / Chimerix, Tecentriq (atezolizumab) / Roche
    Trial completion date:  ONC201 and Atezolizumab in Obesity-Driven Endometrial Cancer (clinicaltrials.gov) -  Jul 10, 2024   
    P1,  N=58, Recruiting, 
    Further understanding of these reactions is crucial for optimizing the safety profile of this groundbreaking immunotherapy. Trial completion date: Jan 2025 --> Jul 2025
  • ||||||||||  Keytruda (pembrolizumab) / Merck (MSD)
    Enrollment open, Trial initiation date, Combination therapy:  Pembrolizumab + Chemotherapy in Newly Diagnosed PCNSL (clinicaltrials.gov) -  Jul 9, 2024   
    P1,  N=15, Recruiting, 
    Not yet recruiting --> Recruiting Not yet recruiting --> Recruiting | Initiation date: Dec 2024 --> Jul 2024
  • ||||||||||  Imdelltra (tarlatamab-dlle) / Amgen
    Journal:  Tarlatamab (Imdelltra) for small cell lung cancer. (Pubmed Central) -  Jul 9, 2024   
    Surgical conversion was feasible in a notable proportion of patients and associated with better survival outcomes. No abstract available
  • ||||||||||  nibrozetone (RRx-001) / EpicentRx
    Journal:  Dissociative Electron Attachment Dynamics of a Promising Cancer Drug Indicates Its Radiosensitizing Potential. (Pubmed Central) -  Jul 9, 2024   
    2-Bromo-1-(3,3-dinitroazetidin-1-yl)ethan-1-one (RRx-001) is a hypoxic cell chemotherapeutics with already demonstrated synergism in combined chemo-radiation therapy...Based on our quantum chemical calculations, we propose that bidirectional intersystem crossing between ?*(NO2) and ?*(C-Br) states explains the experimental spectra. The fast dynamics monitored will impact the condensed phase chemistry of the anion as well.
  • ||||||||||  AUNP-12 / Pierre Fabre
    Preclinical, Journal, Tumor microenvironment, PD(L)-1 Biomarker, IO biomarker:  AUNP-12 Near-Infrared Fluorescence Probes across NIR-I to NIR-II Enable In Vivo Detection of PD-1/PD-L1 Axis in the Tumor Microenvironment. (Pubmed Central) -  Jul 9, 2024   
    These probes have proven to be effective in mapping PD-L1 expression across various mouse tumor models, offering insights into tumor-immune interactions. This study highlights the potential of AUNP-12-Cy5.5 and AUNP-12-CH1055 for guiding clinical immunotherapy through precise patient stratification and dynamic monitoring, supporting the shift toward molecular imaging for personalized cancer care.
  • ||||||||||  Imjudo (tremelimumab) / AstraZeneca, Pfizer, Imfinzi (durvalumab) / AstraZeneca
    Clinical, Journal, Real-world evidence, Real-world:  Initial clinical experience with durvalumab plus tremelimumab in patients with unresectable hepatocellular carcinoma in real?world practice. (Pubmed Central) -  Jul 9, 2024   
    Decision tree analysis revealed that poor liver function and advanced age were significant variables for discontinuation owing to AEs. In conclusion, Dur/Tre as first-line therapy had better disease control responses compared with later-line therapy; however, this regimen should be carefully administered to patients with deteriorating hepatic function or advanced age.
  • ||||||||||  AiRuiKa (camrelizumab) / HLB Bio Group, Lenvima (lenvatinib) / Eisai, Merck (MSD)
    Journal, PD(L)-1 Biomarker:  Prognostic Value of Alpha-Fetoprotein in Unresectable Hepatocellular Carcinoma Treated with Hepatic Artery Infusion Chemotherapy Combined with Lenvatinib and Camrelizumab. (Pubmed Central) -  Jul 9, 2024   
    Multivariate analysis results indicated that both early AFP response and AFP response independently predicted OS [hazard ratio (HR) 2.963, 95% confidence interval (CI) 1.333-6.585, p=0.008, and HR 6.182, 95% CI 1.780-21.466, p=0.004] and PFS (HR 2.186, 95% CI 1.107-4.318, p=0.024, and HR 3.078, 95% CI 1.407-6.730, p=0.005), serving as significant prognostic values. Early AFP response and AFP response serve as predictive biomarkers for the effectiveness of HAIC combined with lenvatinib and camrelizumab in patients with u-HCC.
  • ||||||||||  Rituxan (rituximab) / Roche
    Journal:  Elderly Male With Epstein-Barr Virus (EBV)-Induced Pure Red Cell Aplasia. (Pubmed Central) -  Jul 9, 2024   
    Pure red cell aplasia (PRCA) is a rare hematologic disorder presenting with symptomatic normocytic anemia with preservation of other bone marrow cell lineages that may be acquired in adulthood due to malignancy, autoimmune disease, and infections. PRCA has been attributed to Epstein-Barr virus (EBV) in patients with underlying malignancy; however, we present a rare case of EBV-related PRCA in a previously healthy elderly male without an underlying malignancy who developed transfusion-dependent anemia that responded to glucocorticoids, rituximab, and intravenous immunoglobulins.
  • ||||||||||  Keytruda (pembrolizumab) / Merck (MSD)
    Journal, Checkpoint inhibition, Checkpoint block:  Immune Checkpoint Blockade in Melanoma - Earlier is Better? (Pubmed Central) -  Jul 9, 2024   
    Neoadjuvant ICIs offer advantages like T cell expansion, early-stage efficacy, treatment assessment through surgical specimens, and potential tumor size reduction for better surgical outcomes. However, further research is needed to optimize patient selection and treatment protocols.
  • ||||||||||  Rituxan (rituximab) / Roche, FT596 / Fate Therap
    Trial completion:  FT596 With Rituximab as Relapse Prevention After Autologous HSCT for NHL (clinicaltrials.gov) -  Jul 9, 2024   
    P1,  N=7, Completed, 
    Trial completion date: Dec 2023 --> Dec 2024 Active, not recruiting --> Completed
  • ||||||||||  Opdivo (nivolumab) / BMS
    Trial primary completion date, Metastases:  Nivolumab Combined With SOX Used in the Perioperative Treatment (clinicaltrials.gov) -  Jul 9, 2024   
    P2,  N=46, Recruiting, 
    Active, not recruiting --> Completed Trial primary completion date: Dec 2023 --> Dec 2024
  • ||||||||||  Darzalex (daratumumab) / J&J
    Enrollment closed, Trial completion date, Trial primary completion date:  Steroid Sparing Treatment With in Newly Diagnosed Transplant Ineligible Patients With Multiple Myeloma (clinicaltrials.gov) -  Jul 8, 2024   
    P2,  N=28, Active, not recruiting, 
    Trial completion date: Dec 2024 --> Dec 2025 | Trial primary completion date: Dec 2023 --> Dec 2024 Recruiting --> Active, not recruiting | Trial completion date: Jul 2024 --> Jul 2025 | Trial primary completion date: Jul 2024 --> Jul 2025
  • ||||||||||  Enweida (envafolimab) / 3DMed, Tracon Pharma, Ascletis
    Retrospective data, Journal, Metastases:  Efficacy and Safety of Neoadjuvant Subcutaneous Envafolimab in dMMR/MSI-H Locally Advanced Colon Cancer. (Pubmed Central) -  Jul 8, 2024   
    This meta-analysis highlights the toxicity profiles of anti-angiogenic TKI monotherapies, and thus enables high-level recommendations for the choice of anti-angiogenic TKIs on the basis of the patient's age, ethnicity, comorbidities, and comedications, for personalized treatment. Envafolimab yielded promising surgical outcomes and safety in dMMR/MSI-H locally advanced colon cancer, representing a promising treatment modality for this population.